Artificial Intelligence
Earendil Labs
30-Second Executive Brief
Executive Assessment
Earendil Labs functions as a regional institution within Artificial Intelligence, backed by 47% sourcing coverage, though its relative influence is cooling.
- Maintains 3 mapped relationships across the graph
- 47% sourcing coverage across sourced relationships
- Tracked as regional institution within the Artificial Intelligence category
Executive Snapshot
- Strategic Role
- Regional Institution
- Sourcing Coverage
- 47%
- Ecosystem Influence
- Moderate
- Strategic Momentum
- Decelerating
View Methodology →
Computed live from this entity's own relationships and evidence: how many relationships carry at least one linked citation, weighted with citation recency and source type — independent of Strategic Importance, and not a prediction. Not a hand-typed number; recalculated on every read.
Coverage
- Mapped Relationships
- 3
- Technology Domains
- 5
Strategic Implications
- Central node connecting multiple strategic ecosystems
- Directly influences technology and capital flows
- Material relevance to downstream dependency mapping
Top Opportunities
Top Risks
Critical Dependencies
A Delaware-incorporated, Beijing-headquartered biotech applying machine learning across the entire biologics R&D process, from antibody discovery through development and manufacturing. Earendil raised $787 million in March 2026, backed by Sanofi and the Pfizer/Hillhouse Biotech Development Fund alongside Dimension Capital, DST Global Partners, and Luminous Ventures; its AI-native platform has produced more than 40 programs including HXN-1001, a half-life extended anti-TL1A antibody ready for Phase 2 development, and it holds two major Sanofi licensing deals worth up to $1.72 billion and $2.56 billion in milestones for bispecific antibodies targeting autoimmune diseases.
Sources
Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.
Evidence
2 sources
- BioSpace / PR Newswire — Earendil Labs raises $787M for AI-driven biologics discovery and developmentnews
- PR Newswire — Earendil Labs' two Sanofi licensing deals worth up to $4.28B in combined milestonescompany
Acquisition & Investment Fit
AI-reasoned, generated only from entities already in InsightNodes's own graph — a hypothetical strategic-fit exercise, not real M&A intelligence or a signal that any deal is planned or in progress.
Relationship Map
The relationships surrounding Earendil Labs — ownership, dependencies, regulation, technology and market context. Click any node to make it the new center, 2 levels deep.
Connection type
Click any node to make it the new center. Scroll to zoom, drag to pan.
The Story So Far (last 6 months)
Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.
Market Intelligence
UnverifiedCredibly-reported claims — analyst notes, sourcing citing “people familiar with the matter,” deals where the companies involved declined to comment — that haven't been officially confirmed. Kept structurally separate from the sourced evidence above; treat as a lead worth researching further, not an established fact.
Sanofi's two deals are structured as milestone-heavy bets, not upfront conviction, worth watching for actual cash realization
28% confidenceEarendil Labs' two Sanofi licensing deals carry a combined ~$285 million upfront against up to $4.28 billion in milestones, with the company's Phase 2-ready antibody HXN-1001 and additional IND filings expected in 2026-2027 serving as the near-term proof points for whether those milestones materialize.
This is InsightNodes' own interpretive read: the combined $4.28 billion headline figure across Earendil's two Sanofi deals is overwhelmingly milestone-contingent (roughly $285 million upfront against ~$4 billion in milestones), which is standard biotech dealmaking but means the real test of Earendil's platform is how many of those milestones actually get hit as HXN-1001 and related programs move through IND filings and clinical trials in 2026-2027, not the headline deal value itself.
InsightNodes analysis of Earendil Labs deal structure · Aug 14, 2026
Earendil Labs's Timeline
A sourced, dated history of Earendil Labs's key moments — founding to present.
Apr 2025 · First Sanofi licensing deal for bispecific antibodies
Sanofi paid $125 million upfront (with up to $1.72 billion in milestones) for exclusive global rights to two Earendil-designed bispecific antibodies targeting autoimmune and IBD indications.
Jan 2026 · Second Sanofi deal for additional autoimmune programs
Sanofi arranged a second deal with Earendil worth up to $160 million upfront and $2.56 billion in milestones for additional autoimmune programs from Earendil's AI-native platform.
Mar 2026 · Raises $787M to scale AI-driven biologics platform
Earendil Labs raised $787 million in financing, backed by Sanofi and the Pfizer/Hillhouse Biotech Development Fund alongside Dimension Capital, DST Global Partners, and Luminous Ventures, to scale its AI-native biologics discovery and development platform.